Karus Therapeutics has a track record of success in securing high-quality investment from world-class venture capital companies.

In 2012, Karus secured a Series B investment that was led by new investors, SV Life Sciences, New Leaf Ventures, Novo A/S and International Biotechnology Trust, who joined existing investors, IP Group and a number of Business Angels. This £20m ($30m) investment is being used to advance the company's proprietary PI3K-p110δ/β and HDAC6 inhibitors through early efficacy trials.

The quality of Karus’s investors and their contribution to the Company’s Board of Directors and Scientific Advisory Board is a key driver of success.

Prior to the Series B investment, Karus raised a total of £5m ($7m) through investment rounds in which IP Group and IP Venture Fund participated alongside investors including Esperante, Wyvern Fund, and a number of sector-focused Business Angels.